- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Astellas alleged Janssen’s Erleada nurse support service (package deal) induced prescribing. The Panel found Astellas did not evidence wrongdoing and ruled no…
Pulse ad for Trixeo linked COPD exacerbations and death with a “Take action with Trixeo” call-to-action, creating an unsubstantiated and misleading implication…
A senior UK Pfizer employee retweeted a US colleague’s tweet claiming 95% efficacy for a COVID-19 vaccine candidate before UK authorisation, with…
A Trelegy promotional video summarising an ERS 2022 symposium overstated statistical significance in NMA comparisons on COPD exacerbations, leading to breaches for…
Novo Nordisk failed to disclose some transfers of value on time and did not disclose others at all due to HCO misclassification.…
A third-party LinkedIn post named four AstraZeneca oncology POMs. UK-based AstraZeneca employees ‘liked’ it, which the Panel said disseminated promotional content to…
PMCPA case AUTH/3728/1/23: complaint alleging promotion of Zeposia (ozanimod hydrochloride) against Bristol Myers Squibb. Outcome: no breach; matter not within the scope…
Acepiro (acetylcysteine) banner ad on a learned society homepage lacked the required adverse event reporting statement within the ad itself. Linking to…
Complaint alleged a patient organisation guideline was promotional for Nilemdo/Nustendi and lacked contraindication detail, PI and certification. Panel found Daiichi Sankyo not…
Complaint alleged Sun Pharma phone numbers and website were not functional, potentially affecting patient queries and side effect reporting. Panel found one…
Organon’s Nexplanon ad on a closed doctors’ network was alleged to omit key contraindications and cancer-risk context. Panel found the ad and…
Complaint alleged a senior employee’s LinkedIn ‘Experience’ section promoted Enhertu to the public and off-label, using terms like “blockbuster” and “new”. Panel…
PMCPA found Cipla failed to evidence records of representative interactions with HCPs for nearly two years (Aug 2022–Jul 2024), breaching Clause 5.1…
GSK was found in breach of Clause 25.3 twice after sponsorship of a healthcare organisation’s conference was not clearly acknowledged from the…
A PCT pharmacist alleged a Teva-supported supplement about switching to CFC-free beclometasone inhalers was disguised promotion for Qvar. The Panel ruled Teva’s…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.